LOGIN  |  REGISTER
Viking Therapeutics
Cue Biopharma

R1 RCM to Host a Virtual Event “Technology Teach-In: A Deep Dive into Key Focus Areas and the R1 Platform” on June 27, 2024

June 17, 2024 | Last Trade: US$14.31 0.00 0.00

MURRAY, Utah, June 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1” or the “Company”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced it will host a virtual event on Thursday, June 27, 2024 at 11:00 AM ET. To register, click here.

The event will feature Steve Albert, Executive Vice President and Chief Product Officer, and Brian Gambs, Executive Vice President and Chief Technology Officer. Steve and Brian will provide an overview of the R1 Platform and key areas of innovation as well as value creation for R1 and its customers. They will also highlight key advantages of the platform, new AI innovation, and select focus areas of R1’s future technology roadmap. A live question and answer session will follow the formal presentation.

A live audio webcast of this presentation will be available on the Investor Relations section of R1’s website at r1rcm.com. A replay of the webcast will be available for 90 days following the live webcast.

About R1 RCM

R1 is a leading provider of technology-driven solutions that transform the financial performance and patient experience for health systems, hospitals, and physician groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while driving revenue yield, reducing operating costs, and enhancing the patient experience. To learn more, visit: www.r1rcm.com

Contacts:

Investor Relations:
Evan Smith, CFA
516-743-5184
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact:
Josh Blumenthal
This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB